Genetic testing study to boost medication response starts in Glasgow
The landmark trial will recruit up to 4,000 patients over the next two years in the NHS Greater Glasgow and Clyde area, to investigate how an individual's genetic profile affects their response to 60 common medications.
It is hoped the Phoenix Study will to lead to wider implementation of genetic testing across Scotland, making 'precision medicine' routine, for the first time.
Researchers hope it will pave the way for tailored prescribing across cardiology, stroke, surgery, orthopaedics, geriatrics, gynaecology, ENT, rheumatology, respiratory, neurology, psychiatry and other specialities.
The trial will take place at the Queen Elizabeth University Hospital (QEUH) in Glasgow.
Pharmacogenomics (PGx) – the study of how genes influence individual responses to drugs – has not been routinely used in clinical practice in the UK, amid hopes evidence will lead to change.
Genetic test results will be sent to clinicians, allowing for treatment decisions to be adjusted, and patients will be followed up regularly to monitor the effects of any changes, to ensure they receive the highest standard of care.
Patients will undergo a simple genetic test to analyse their DNA and the results, returned within days, will help doctors determine whether each patient is receiving the most suitable drug and dosage based on their genetic make-up.
Around 15% are expected to carry genetic variants that may reduce the effectiveness of a medication or increase the risk of side-effects.
In some cases, the prescribed drug may be ineffective, or a different dosage may be needed.
The trial is open to adult in-patients in the QEUH and patients will be randomly assigned to either receive the pharmacogenomic test immediately, or at three months, which will allow the researchers to establish evidence of benefit.
Without prior testing, these issues can go unnoticed, often leading to a trial-and-error approach to treatment, according to researchers.
It is led by Sandosh Padmanabhan, Pontecorvo chair of Pharmacogenomics at the University of Glasgow, in partnership with the University of Glasgow's Living Laboratory, the NHSGGC-hosted West of Scotland Innovation Hub, and industry partners MyDNA and Agena Bioscience.
Patient Eric Balish was asked to take part by consultants, after having a heart attack and subsequent surgery.
He was immediately prescribed clopidogrel, one of the 60 drugs included in the study, but has since had his medication changed a number of times.
Mr Balish said: 'I knew a bit about personalised medicine previously, and so when I was asked to take part in the Phoenix Study I was happy to do it.
'If you're asked to participate and support long-term research like this, then it's no great hardship to give something back and just do the right thing. I am hopeful my information can be of use to the trial and in the future.'
Prof Padmanabhan, a consultant at the QEUH, said: 'Physicians and pharmacists increasingly recognise that PGx-informed prescribing and dispensing improves both the efficacy and safety of drug treatment.
'The primary goal of this trial is to evaluate the clinical and health-economic impact of PGx-guided prescribing.
'Specifically, we want to determine if a PGx-guided approach to prescribing can significantly reduce the incidence and severity of drug related side-effects and/or treatment failures.
'This evaluation will compare the outcomes of participants who receive PGx-guided medication management to those receiving standard care.'
Dr Katriona Brooksbank, research and innovation lead for NHSGGC and the West of Scotland Innovation Hub, said: 'We are incredibly excited to be supporting this trial, which could have a major impact on the treatments patients are prescribed based on their own genetics.
'It will put precision medicine into action as researchers look to determine how a person's own genetic make-up can affect the drugs they are given as treatments.
'This could allow clinicians to reduce adverse reactions and side effects, ensuring the best possible outcomes for patients.'
Allan Sheffield, co-founder of MyDNA, said: 'For MyDNA, the Phoenix Study embodies the future of healthcare.
'Our unique combination of pharmacogenomic clinical decision support and in-house Gene by Gene accredited testing empowers clinicians to move beyond guesswork.
'This trial will demonstrate the profound impact of precision medicine, paving the way for a future where this approach routinely drives better patient outcomes.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Glasgow Times
4 days ago
- Glasgow Times
Glasgow University study sheds light on Alzheimer's risk
The research, led by the University of Glasgow, published in the journal npj Dementia, found that while better memory, reasoning, and reaction times were linked to a lower risk of Alzheimer's disease up to 15 years later, this protective effect was significantly reduced in people with a higher genetic risk. Researchers focused on the APOE e4 genotype, which is present in roughly one in four people and is the strongest known genetic predictor of late-onset Alzheimer's. Read more: Glasgow drugs trial to use genetics to 'personalise' treatments A single copy of the APOE e4 gene increases Alzheimer's risk threefold, while two copies raise the risk by twelvefold. Dr Donald Lyall, senior lecturer in population brain health at the University of Glasgow's School of Health and Wellbeing, said: "Our study adds to the knowledge gap that exists on the relationship between genetic factors, cognitive health generally, and subsequent risk of dementia in later life. "Our findings suggest that genetics plays a more significant role than previously thought and may influence the risk or protection conferred by other factors like premorbid cognitive health." In the study, people with above-average reasoning ability were found to have a 36% lower risk of developing Alzheimer's within 15 years. However, for those who also carried the APOE e4 gene, the risk reduction dropped to just 21%. More strikingly, individuals with high reasoning skills but who carried the APOE e4 genotype were more likely to develop Alzheimer's than those with below-average reasoning but no genetic risk factor. The researchers analysed data from over 252,000 UK Biobank participants aged 55 and older, with the average age at the start of the study being just over 62. To ensure long-term accuracy, individuals diagnosed with Alzheimer's within two years of testing were excluded. Researchers excluded individuals diagnosed with Alzheimer's within two years of cognitive testing. The study reinforces the challenges in identifying effective therapies for Alzheimer's, particularly given the influence of genetic factors. Read more: Public urged to shape health board's anti-racism strategy - how you can help Dr Lyall said: "Our study has important implications regarding dementia; namely that genetics clearly plays a significant role in influencing someone's overall risk of Alzheimer's disease as they age." The findings underscore the complex interplay between cognitive health and genetics and the challenges in developing therapies that can effectively prevent or treat Alzheimer's. While cognitive resilience still matters, the research highlights the urgent need to understand genetic risk factors in the fight against one of the world's most devastating neurodegenerative conditions.
STV News
5 days ago
- STV News
Genetic testing study 'could help personalise treatments for patients'
A new study aims to show how genetic testing could help personalise treatments by boosting medication response and reducing harmful side effects. The landmark trial will recruit up to 4,000 patients over the next two years in the NHS Greater Glasgow and Clyde area, to investigate how an individual's genetic profile affects their response to 60 common medications. It is hoped the Phoenix Study will to lead to wider implementation of genetic testing across Scotland, making 'precision medicine' routine, for the first time. Researchers hope it will pave the way for tailored prescribing across cardiology, stroke, surgery, orthopaedics, geriatrics, gynaecology, ENT, rheumatology, respiratory, neurology, psychiatry and other specialities. The trial will take place at the Queen Elizabeth University Hospital (QEUH) in Glasgow. Pharmacogenomics (PGx) – the study of how genes influence individual responses to drugs – has not been routinely used in clinical practice in the UK, amid hopes evidence will lead to change. Genetic test results will be sent to clinicians, allowing for treatment decisions to be adjusted, and patients will be followed up regularly to monitor the effects of any changes, to ensure they receive the highest standard of care. Patients will undergo a simple genetic test to analyse their DNA and the results, returned within days, will help doctors determine whether each patient is receiving the most suitable drug and dosage based on their genetic make-up. Around 15% are expected to carry genetic variants that may reduce the effectiveness of a medication or increase the risk of side-effects. In some cases, the prescribed drug may be ineffective, or a different dosage may be needed. The trial is open to adult in-patients in the QEUH and patients will be randomly assigned to either receive the pharmacogenomic test immediately, or at three months, which will allow the researchers to establish evidence of benefit. Without prior testing, these issues can go unnoticed, often leading to a trial-and-error approach to treatment, according to researchers. It is led by Sandosh Padmanabhan, Pontecorvo chair of Pharmacogenomics at the University of Glasgow, in partnership with the University of Glasgow's Living Laboratory, the NHSGGC-hosted West of Scotland Innovation Hub, and industry partners MyDNA and Agena Bioscience. Patient Eric Balish was asked to take part by consultants, after having a heart attack and subsequent surgery. He was immediately prescribed clopidogrel, one of the 60 drugs included in the study, but has since had his medication changed a number of times. Mr Balish said: 'I knew a bit about personalised medicine previously, and so when I was asked to take part in the Phoenix Study I was happy to do it. 'If you're asked to participate and support long-term research like this, then it's no great hardship to give something back and just do the right thing. I am hopeful my information can be of use to the trial and in the future.' Prof Padmanabhan, a consultant at the QEUH, said: 'Physicians and pharmacists increasingly recognise that PGx-informed prescribing and dispensing improves both the efficacy and safety of drug treatment. 'The primary goal of this trial is to evaluate the clinical and health-economic impact of PGx-guided prescribing. 'Specifically, we want to determine if a PGx-guided approach to prescribing can significantly reduce the incidence and severity of drug related side-effects and/or treatment failures. 'This evaluation will compare the outcomes of participants who receive PGx-guided medication management to those receiving standard care.' Dr Katriona Brooksbank, research and innovation lead for NHSGGC and the West of Scotland Innovation Hub, said: 'We are incredibly excited to be supporting this trial, which could have a major impact on the treatments patients are prescribed based on their own genetics. 'It will put precision medicine into action as researchers look to determine how a person's own genetic make-up can affect the drugs they are given as treatments. 'This could allow clinicians to reduce adverse reactions and side effects, ensuring the best possible outcomes for patients.' Allan Sheffield, co-founder of MyDNA, said: 'For MyDNA, the Phoenix Study embodies the future of healthcare. 'Our unique combination of pharmacogenomic clinical decision support and in-house Gene by Gene accredited testing empowers clinicians to move beyond guesswork. 'This trial will demonstrate the profound impact of precision medicine, paving the way for a future where this approach routinely drives better patient outcomes.' Get all the latest news from around the country Follow STV News Scan the QR code on your mobile device for all the latest news from around the country
Rhyl Journal
5 days ago
- Rhyl Journal
Genetic testing study to boost medication response starts in Glasgow
The landmark trial will recruit up to 4,000 patients over the next two years in the NHS Greater Glasgow and Clyde area, to investigate how an individual's genetic profile affects their response to 60 common medications. It is hoped the Phoenix Study will to lead to wider implementation of genetic testing across Scotland, making 'precision medicine' routine, for the first time. Researchers hope it will pave the way for tailored prescribing across cardiology, stroke, surgery, orthopaedics, geriatrics, gynaecology, ENT, rheumatology, respiratory, neurology, psychiatry and other specialities. The trial will take place at the Queen Elizabeth University Hospital (QEUH) in Glasgow. Pharmacogenomics (PGx) – the study of how genes influence individual responses to drugs – has not been routinely used in clinical practice in the UK, amid hopes evidence will lead to change. Genetic test results will be sent to clinicians, allowing for treatment decisions to be adjusted, and patients will be followed up regularly to monitor the effects of any changes, to ensure they receive the highest standard of care. Patients will undergo a simple genetic test to analyse their DNA and the results, returned within days, will help doctors determine whether each patient is receiving the most suitable drug and dosage based on their genetic make-up. Around 15% are expected to carry genetic variants that may reduce the effectiveness of a medication or increase the risk of side-effects. In some cases, the prescribed drug may be ineffective, or a different dosage may be needed. The trial is open to adult in-patients in the QEUH and patients will be randomly assigned to either receive the pharmacogenomic test immediately, or at three months, which will allow the researchers to establish evidence of benefit. Without prior testing, these issues can go unnoticed, often leading to a trial-and-error approach to treatment, according to researchers. It is led by Sandosh Padmanabhan, Pontecorvo chair of Pharmacogenomics at the University of Glasgow, in partnership with the University of Glasgow's Living Laboratory, the NHSGGC-hosted West of Scotland Innovation Hub, and industry partners MyDNA and Agena Bioscience. Patient Eric Balish was asked to take part by consultants, after having a heart attack and subsequent surgery. He was immediately prescribed clopidogrel, one of the 60 drugs included in the study, but has since had his medication changed a number of times. Mr Balish said: 'I knew a bit about personalised medicine previously, and so when I was asked to take part in the Phoenix Study I was happy to do it. 'If you're asked to participate and support long-term research like this, then it's no great hardship to give something back and just do the right thing. I am hopeful my information can be of use to the trial and in the future.' Prof Padmanabhan, a consultant at the QEUH, said: 'Physicians and pharmacists increasingly recognise that PGx-informed prescribing and dispensing improves both the efficacy and safety of drug treatment. 'The primary goal of this trial is to evaluate the clinical and health-economic impact of PGx-guided prescribing. 'Specifically, we want to determine if a PGx-guided approach to prescribing can significantly reduce the incidence and severity of drug related side-effects and/or treatment failures. 'This evaluation will compare the outcomes of participants who receive PGx-guided medication management to those receiving standard care.' Dr Katriona Brooksbank, research and innovation lead for NHSGGC and the West of Scotland Innovation Hub, said: 'We are incredibly excited to be supporting this trial, which could have a major impact on the treatments patients are prescribed based on their own genetics. 'It will put precision medicine into action as researchers look to determine how a person's own genetic make-up can affect the drugs they are given as treatments. 'This could allow clinicians to reduce adverse reactions and side effects, ensuring the best possible outcomes for patients.' Allan Sheffield, co-founder of MyDNA, said: 'For MyDNA, the Phoenix Study embodies the future of healthcare. 'Our unique combination of pharmacogenomic clinical decision support and in-house Gene by Gene accredited testing empowers clinicians to move beyond guesswork. 'This trial will demonstrate the profound impact of precision medicine, paving the way for a future where this approach routinely drives better patient outcomes.'
